DE69721484D1 - Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten - Google Patents

Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten

Info

Publication number
DE69721484D1
DE69721484D1 DE69721484T DE69721484T DE69721484D1 DE 69721484 D1 DE69721484 D1 DE 69721484D1 DE 69721484 T DE69721484 T DE 69721484T DE 69721484 T DE69721484 T DE 69721484T DE 69721484 D1 DE69721484 D1 DE 69721484D1
Authority
DE
Germany
Prior art keywords
treatment
nucleoside derivatives
combination preparations
hsv
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69721484T
Other languages
English (en)
Other versions
DE69721484T2 (de
Inventor
Malcolm Richard Boyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis International Pharmaceutical Ltd
Original Assignee
Novartis International Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10787583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69721484(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis International Pharmaceutical Ltd filed Critical Novartis International Pharmaceutical Ltd
Application granted granted Critical
Publication of DE69721484D1 publication Critical patent/DE69721484D1/de
Publication of DE69721484T2 publication Critical patent/DE69721484T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69721484T 1996-01-26 1997-01-24 Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten Expired - Fee Related DE69721484T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9601544 1996-01-26
GBGB9601544.1A GB9601544D0 (en) 1996-01-26 1996-01-26 Pharmaceuticals
PCT/GB1997/000226 WO1997026882A1 (en) 1996-01-26 1997-01-24 Nucleoside analogs in combination therapy of herpes simplex infections

Publications (2)

Publication Number Publication Date
DE69721484D1 true DE69721484D1 (de) 2003-06-05
DE69721484T2 DE69721484T2 (de) 2004-02-26

Family

ID=10787583

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721484T Expired - Fee Related DE69721484T2 (de) 1996-01-26 1997-01-24 Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten

Country Status (26)

Country Link
US (5) US6514980B1 (de)
EP (1) EP0876146B1 (de)
JP (1) JP2000507211A (de)
KR (1) KR19990081966A (de)
CN (1) CN1133433C (de)
AR (1) AR005551A1 (de)
AT (1) ATE238796T1 (de)
AU (1) AU713202B2 (de)
BR (1) BR9707304A (de)
CY (1) CY2421B1 (de)
CZ (1) CZ297841B6 (de)
DE (1) DE69721484T2 (de)
DK (1) DK0876146T3 (de)
ES (1) ES2199339T3 (de)
GB (1) GB9601544D0 (de)
HK (1) HK1016475A1 (de)
HU (1) HU226793B1 (de)
IL (1) IL125075A (de)
NO (1) NO316355B1 (de)
NZ (1) NZ326839A (de)
PL (1) PL187076B1 (de)
PT (1) PT876146E (de)
TR (1) TR199801439T2 (de)
TW (1) TW493985B (de)
WO (1) WO1997026882A1 (de)
ZA (1) ZA97608B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ1966A1 (fr) 1995-02-06 2002-10-15 Astra Ab Combinaison pharmaceutique nouvelle.
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
US7591945B2 (en) * 2003-02-07 2009-09-22 Gambro Lundia Ab Support device for containers in extracorporeal blood treatment machines
CN101193643A (zh) * 2005-03-25 2008-06-04 Alt解决方案公司 端粒酶阳性细胞中端粒长度的调节和癌症治疗
US8609623B2 (en) * 2005-05-18 2013-12-17 Alt Solutions Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
WO2011035120A2 (en) * 2009-09-17 2011-03-24 Gk Ventures, L.L.C. Therapeutic composition to treat lesions caused by herpes simplex virus
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
CN112704154A (zh) * 2020-12-24 2021-04-27 中国人民解放军66399部队 一种用于治疗宠物猫疱疹病毒的营养膏

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317384A (en) * 1964-06-08 1967-05-02 Upjohn Co Treatment of topical viral infections with glucocorticoids and nucleosides
US3322627A (en) * 1964-09-03 1967-05-30 Merck & Co Inc Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor
GB9001886D0 (en) * 1990-01-26 1990-03-28 Beecham Group Plc Pharmaceutical formulation
GB9015051D0 (en) * 1990-07-07 1990-08-29 Beecham Group Plc Pharmaceutical treatment
EP0609606B1 (de) 1992-10-01 1996-12-11 The Wellcome Foundation Limited Tucaresol als Mittel zur Immunopotentierung
GB9426021D0 (en) 1994-12-22 1995-02-22 Smithkline Beecham Plc Pharmaceuticals
DZ1966A1 (fr) * 1995-02-06 2002-10-15 Astra Ab Combinaison pharmaceutique nouvelle.
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
DE69721484T2 (de) 2004-02-26
NZ326839A (en) 2001-02-23
US20040185433A1 (en) 2004-09-23
HUP9900945A3 (en) 2001-02-28
HK1016475A1 (en) 1999-11-05
TR199801439T2 (xx) 1998-10-21
AU1550697A (en) 1997-08-20
US20050222016A1 (en) 2005-10-06
NO316355B1 (no) 2004-01-19
PT876146E (pt) 2003-09-30
US20100323952A1 (en) 2010-12-23
CZ297841B6 (cs) 2007-04-11
KR19990081966A (ko) 1999-11-15
JP2000507211A (ja) 2000-06-13
HUP9900945A2 (hu) 1999-07-28
NO983402L (no) 1998-07-23
IL125075A (en) 2003-02-12
ZA97608B (en) 1998-07-24
NO983402D0 (no) 1998-07-23
AR005551A1 (es) 1999-06-23
CZ234098A3 (cs) 1999-02-17
CY2421B1 (en) 2004-11-12
PL327917A1 (en) 1999-01-04
IL125075A0 (en) 1999-01-26
TW493985B (en) 2002-07-11
GB9601544D0 (en) 1996-03-27
BR9707304A (pt) 1999-07-20
AU713202B2 (en) 1999-11-25
WO1997026882A1 (en) 1997-07-31
CN1209748A (zh) 1999-03-03
DK0876146T3 (da) 2003-08-11
PL187076B1 (pl) 2004-05-31
ES2199339T3 (es) 2004-02-16
CN1133433C (zh) 2004-01-07
US20080287389A1 (en) 2008-11-20
US6514980B1 (en) 2003-02-04
ATE238796T1 (de) 2003-05-15
EP0876146B1 (de) 2003-05-02
HU226793B1 (en) 2009-10-28
EP0876146A1 (de) 1998-11-11

Similar Documents

Publication Publication Date Title
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69711311T2 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69807466T2 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DE69813354T2 (de) Mittel zur Behandlung von Herzkrankheiten
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
ATA93695A (de) Mittel zur behandlung von strahlenschäden

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 876146

Country of ref document: EP

Effective date: 20110802

R082 Change of representative

Ref document number: 876146

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE